A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...

This new article publication from Acta Pharmaceutica Sinica B, discusses a bispecific killer engager for targeted depletion ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Subcutaneous LCMV infection induces T H 1 cell ...

For example, primary immunodeficiency disease (PID) is diagnosed with a deficiency of total IgG. An antibody test can confirm that an infection has taken place, as with COVID-19 or HIV, although it ...

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...

“Deep B-cell depletion ... Dren has another antibody in development in the form of DR-01, which is designed to selectively deplete cytotoxic cells such as autoreactive CD8 T cells.

Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a ...